Covid-19 Impact on Global Scleroderma Therapeutics Market Size, Status and Forecast 2020-2026
Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.
The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Scleroderma Therapeutics market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Scleroderma Therapeutics industry.
Based on our recent survey, we have several different scenarios about the Scleroderma Therapeutics YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 1394.4 million in 2019. The market size of Scleroderma Therapeutics will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Scleroderma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Scleroderma Therapeutics market in terms of revenue.
Players, stakeholders, and other participants in the global Scleroderma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Scleroderma Therapeutics market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Scleroderma Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Scleroderma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Scleroderma Therapeutics market.
The following players are covered in this report:
The market is mainly driven by the off-label use of drugs approved for its symptomatic indications, such as rheumatoid arthritis.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Scleroderma Therapeutics market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Scleroderma Therapeutics industry.
Based on our recent survey, we have several different scenarios about the Scleroderma Therapeutics YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 1394.4 million in 2019. The market size of Scleroderma Therapeutics will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Scleroderma Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Scleroderma Therapeutics market in terms of revenue.
Players, stakeholders, and other participants in the global Scleroderma Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Scleroderma Therapeutics market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Scleroderma Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Scleroderma Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Scleroderma Therapeutics market.
The following players are covered in this report:
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Celgene Corporation
- Argentis Pharmaceuticals, LLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Akashi Therapeutics
- Prometic Life Sciences, Inc.
- Emerald Health Pharmaceuticals
- Kadmon Holdings, Inc.
- Seattle Genetics, Inc.
- Cytori Therapeutics, Inc.
- Fibrocell Science, Inc.
- Chemomab
- Corbus Pharmaceuticals Holdings, Inc.
- Genkyotex
- Immunosuppressors
- Phosphodiesterase 5 Inhibitors - PHA
- Endothelin Receptor Antagonists
- Prostacyclin Analogues
- Calcium Channel Blockers
- Analgesics
- Others
- Systemic
- Localized
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Immunosuppressors
1.4.3 Phosphodiesterase 5 Inhibitors - PHA
1.4.4 Endothelin Receptor Antagonists
1.4.5 Prostacyclin Analogues
1.4.6 Calcium Channel Blockers
1.4.7 Analgesics
1.4.8 Others
1.5 Market by Application
1.5.1 Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Systemic
1.5.3 Localized
1.6 Coronavirus Disease 2019 (Covid-19): Scleroderma Therapeutics Industry Impact
1.6.1 How the Covid-19 is Affecting the Scleroderma Therapeutics Industry
1.6.1.1 Scleroderma Therapeutics Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Scleroderma Therapeutics Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Scleroderma Therapeutics Market Perspective (2015-2026)
2.2 Scleroderma Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Scleroderma Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Scleroderma Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Scleroderma Therapeutics Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Scleroderma Therapeutics Players by Market Size
3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Scleroderma Therapeutics Market Concentration Ratio
3.2.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2019
3.3 Scleroderma Therapeutics Key Players Head office and Area Served
3.4 Key Players Scleroderma Therapeutics Product Solution and Service
3.5 Date of Enter into Scleroderma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2021-2026)
5 SCLERODERMA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Scleroderma Therapeutics Market Size by Application (2015-2020)
5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Scleroderma Therapeutics Market Size (2015-2020)
6.2 Scleroderma Therapeutics Key Players in North America (2019-2020)
6.3 North America Scleroderma Therapeutics Market Size by Type (2015-2020)
6.4 North America Scleroderma Therapeutics Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Scleroderma Therapeutics Market Size (2015-2020)
7.2 Scleroderma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Scleroderma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Scleroderma Therapeutics Market Size by Application (2015-2020)
8 CHINA
8.1 China Scleroderma Therapeutics Market Size (2015-2020)
8.2 Scleroderma Therapeutics Key Players in China (2019-2020)
8.3 China Scleroderma Therapeutics Market Size by Type (2015-2020)
8.4 China Scleroderma Therapeutics Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Scleroderma Therapeutics Market Size (2015-2020)
9.2 Scleroderma Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Scleroderma Therapeutics Market Size by Type (2015-2020)
9.4 Japan Scleroderma Therapeutics Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Scleroderma Therapeutics Market Size (2015-2020)
10.2 Scleroderma Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Scleroderma Therapeutics Market Size by Application (2015-2020)
11 INDIA
11.1 India Scleroderma Therapeutics Market Size (2015-2020)
11.2 Scleroderma Therapeutics Key Players in India (2019-2020)
11.3 India Scleroderma Therapeutics Market Size by Type (2015-2020)
11.4 India Scleroderma Therapeutics Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Scleroderma Therapeutics Market Size (2015-2020)
12.2 Scleroderma Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Scleroderma Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Scleroderma Therapeutics Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 F. Hoffmann-La Roche AG
13.1.1 F. Hoffmann-La Roche AG Company Details
13.1.2 F. Hoffmann-La Roche AG Business Overview and Its Total Revenue
13.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
13.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2015-2020))
13.1.5 F. Hoffmann-La Roche AG Recent Development
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Details
13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
13.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
13.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2015-2020)
13.2.5 Bristol-Myers Squibb Company Recent Development
13.3 Celgene Corporation
13.3.1 Celgene Corporation Company Details
13.3.2 Celgene Corporation Business Overview and Its Total Revenue
13.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
13.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2015-2020)
13.3.5 Celgene Corporation Recent Development
13.4 Argentis Pharmaceuticals, LLC
13.4.1 Argentis Pharmaceuticals, LLC Company Details
13.4.2 Argentis Pharmaceuticals, LLC Business Overview and Its Total Revenue
13.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
13.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2015-2020)
13.4.5 Argentis Pharmaceuticals, LLC Recent Development
13.5 Bayer AG
13.5.1 Bayer AG Company Details
13.5.2 Bayer AG Business Overview and Its Total Revenue
13.5.3 Bayer AG Scleroderma Therapeutics Introduction
13.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020)
13.5.5 Bayer AG Recent Development
13.6 Boehringer Ingelheim International GmbH
13.6.1 Boehringer Ingelheim International GmbH Company Details
13.6.2 Boehringer Ingelheim International GmbH Business Overview and Its Total Revenue
13.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
13.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020)
13.6.5 Boehringer Ingelheim International GmbH Recent Development
13.7 Akashi Therapeutics
13.7.1 Akashi Therapeutics Company Details
13.7.2 Akashi Therapeutics Business Overview and Its Total Revenue
13.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
13.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020)
13.7.5 Akashi Therapeutics Recent Development
13.8 Prometic Life Sciences, Inc.
13.8.1 Prometic Life Sciences, Inc. Company Details
13.8.2 Prometic Life Sciences, Inc. Business Overview and Its Total Revenue
13.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
13.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
13.8.5 Prometic Life Sciences, Inc. Recent Development
13.9 Emerald Health Pharmaceuticals
13.9.1 Emerald Health Pharmaceuticals Company Details
13.9.2 Emerald Health Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
13.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020)
13.9.5 Emerald Health Pharmaceuticals Recent Development
13.10 Kadmon Holdings, Inc.
13.10.1 Kadmon Holdings, Inc. Company Details
13.10.2 Kadmon Holdings, Inc. Business Overview and Its Total Revenue
13.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
13.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
13.10.5 Kadmon Holdings, Inc. Recent Development
13.11 Seattle Genetics, Inc.
10.11.1 Seattle Genetics, Inc. Company Details
10.11.2 Seattle Genetics, Inc. Business Overview and Its Total Revenue
10.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
10.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.11.5 Seattle Genetics, Inc. Recent Development
13.12 Cytori Therapeutics, Inc.
10.12.1 Cytori Therapeutics, Inc. Company Details
10.12.2 Cytori Therapeutics, Inc. Business Overview and Its Total Revenue
10.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
10.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.12.5 Cytori Therapeutics, Inc. Recent Development
13.13 Fibrocell Science, Inc.
10.13.1 Fibrocell Science, Inc. Company Details
10.13.2 Fibrocell Science, Inc. Business Overview and Its Total Revenue
10.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
10.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.13.5 Fibrocell Science, Inc. Recent Development
13.14 Chemomab
10.14.1 Chemomab Company Details
10.14.2 Chemomab Business Overview and Its Total Revenue
10.14.3 Chemomab Scleroderma Therapeutics Introduction
10.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020)
10.14.5 Chemomab Recent Development
13.15 Corbus Pharmaceuticals Holdings, Inc.
10.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details
10.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview and Its Total Revenue
10.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
10.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development
13.16 Genkyotex
10.16.1 Genkyotex Company Details
10.16.2 Genkyotex Business Overview and Its Total Revenue
10.16.3 Genkyotex Scleroderma Therapeutics Introduction
10.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020)
10.16.5 Genkyotex Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Scleroderma Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Scleroderma Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Immunosuppressors
1.4.3 Phosphodiesterase 5 Inhibitors - PHA
1.4.4 Endothelin Receptor Antagonists
1.4.5 Prostacyclin Analogues
1.4.6 Calcium Channel Blockers
1.4.7 Analgesics
1.4.8 Others
1.5 Market by Application
1.5.1 Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Systemic
1.5.3 Localized
1.6 Coronavirus Disease 2019 (Covid-19): Scleroderma Therapeutics Industry Impact
1.6.1 How the Covid-19 is Affecting the Scleroderma Therapeutics Industry
1.6.1.1 Scleroderma Therapeutics Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Scleroderma Therapeutics Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Scleroderma Therapeutics Market Perspective (2015-2026)
2.2 Scleroderma Therapeutics Growth Trends by Regions
2.2.1 Scleroderma Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Scleroderma Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Scleroderma Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Scleroderma Therapeutics Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Scleroderma Therapeutics Players by Market Size
3.1.1 Global Top Scleroderma Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Scleroderma Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Scleroderma Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Scleroderma Therapeutics Market Concentration Ratio
3.2.1 Global Scleroderma Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Scleroderma Therapeutics Revenue in 2019
3.3 Scleroderma Therapeutics Key Players Head office and Area Served
3.4 Key Players Scleroderma Therapeutics Product Solution and Service
3.5 Date of Enter into Scleroderma Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Scleroderma Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Scleroderma Therapeutics Forecasted Market Size by Type (2021-2026)
5 SCLERODERMA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Scleroderma Therapeutics Market Size by Application (2015-2020)
5.2 Global Scleroderma Therapeutics Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Scleroderma Therapeutics Market Size (2015-2020)
6.2 Scleroderma Therapeutics Key Players in North America (2019-2020)
6.3 North America Scleroderma Therapeutics Market Size by Type (2015-2020)
6.4 North America Scleroderma Therapeutics Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Scleroderma Therapeutics Market Size (2015-2020)
7.2 Scleroderma Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Scleroderma Therapeutics Market Size by Type (2015-2020)
7.4 Europe Scleroderma Therapeutics Market Size by Application (2015-2020)
8 CHINA
8.1 China Scleroderma Therapeutics Market Size (2015-2020)
8.2 Scleroderma Therapeutics Key Players in China (2019-2020)
8.3 China Scleroderma Therapeutics Market Size by Type (2015-2020)
8.4 China Scleroderma Therapeutics Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Scleroderma Therapeutics Market Size (2015-2020)
9.2 Scleroderma Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Scleroderma Therapeutics Market Size by Type (2015-2020)
9.4 Japan Scleroderma Therapeutics Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Scleroderma Therapeutics Market Size (2015-2020)
10.2 Scleroderma Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Scleroderma Therapeutics Market Size by Application (2015-2020)
11 INDIA
11.1 India Scleroderma Therapeutics Market Size (2015-2020)
11.2 Scleroderma Therapeutics Key Players in India (2019-2020)
11.3 India Scleroderma Therapeutics Market Size by Type (2015-2020)
11.4 India Scleroderma Therapeutics Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Scleroderma Therapeutics Market Size (2015-2020)
12.2 Scleroderma Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Scleroderma Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Scleroderma Therapeutics Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 F. Hoffmann-La Roche AG
13.1.1 F. Hoffmann-La Roche AG Company Details
13.1.2 F. Hoffmann-La Roche AG Business Overview and Its Total Revenue
13.1.3 F. Hoffmann-La Roche AG Scleroderma Therapeutics Introduction
13.1.4 F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2015-2020))
13.1.5 F. Hoffmann-La Roche AG Recent Development
13.2 Bristol-Myers Squibb Company
13.2.1 Bristol-Myers Squibb Company Company Details
13.2.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
13.2.3 Bristol-Myers Squibb Company Scleroderma Therapeutics Introduction
13.2.4 Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2015-2020)
13.2.5 Bristol-Myers Squibb Company Recent Development
13.3 Celgene Corporation
13.3.1 Celgene Corporation Company Details
13.3.2 Celgene Corporation Business Overview and Its Total Revenue
13.3.3 Celgene Corporation Scleroderma Therapeutics Introduction
13.3.4 Celgene Corporation Revenue in Scleroderma Therapeutics Business (2015-2020)
13.3.5 Celgene Corporation Recent Development
13.4 Argentis Pharmaceuticals, LLC
13.4.1 Argentis Pharmaceuticals, LLC Company Details
13.4.2 Argentis Pharmaceuticals, LLC Business Overview and Its Total Revenue
13.4.3 Argentis Pharmaceuticals, LLC Scleroderma Therapeutics Introduction
13.4.4 Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2015-2020)
13.4.5 Argentis Pharmaceuticals, LLC Recent Development
13.5 Bayer AG
13.5.1 Bayer AG Company Details
13.5.2 Bayer AG Business Overview and Its Total Revenue
13.5.3 Bayer AG Scleroderma Therapeutics Introduction
13.5.4 Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020)
13.5.5 Bayer AG Recent Development
13.6 Boehringer Ingelheim International GmbH
13.6.1 Boehringer Ingelheim International GmbH Company Details
13.6.2 Boehringer Ingelheim International GmbH Business Overview and Its Total Revenue
13.6.3 Boehringer Ingelheim International GmbH Scleroderma Therapeutics Introduction
13.6.4 Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020)
13.6.5 Boehringer Ingelheim International GmbH Recent Development
13.7 Akashi Therapeutics
13.7.1 Akashi Therapeutics Company Details
13.7.2 Akashi Therapeutics Business Overview and Its Total Revenue
13.7.3 Akashi Therapeutics Scleroderma Therapeutics Introduction
13.7.4 Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020)
13.7.5 Akashi Therapeutics Recent Development
13.8 Prometic Life Sciences, Inc.
13.8.1 Prometic Life Sciences, Inc. Company Details
13.8.2 Prometic Life Sciences, Inc. Business Overview and Its Total Revenue
13.8.3 Prometic Life Sciences, Inc. Scleroderma Therapeutics Introduction
13.8.4 Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
13.8.5 Prometic Life Sciences, Inc. Recent Development
13.9 Emerald Health Pharmaceuticals
13.9.1 Emerald Health Pharmaceuticals Company Details
13.9.2 Emerald Health Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Emerald Health Pharmaceuticals Scleroderma Therapeutics Introduction
13.9.4 Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020)
13.9.5 Emerald Health Pharmaceuticals Recent Development
13.10 Kadmon Holdings, Inc.
13.10.1 Kadmon Holdings, Inc. Company Details
13.10.2 Kadmon Holdings, Inc. Business Overview and Its Total Revenue
13.10.3 Kadmon Holdings, Inc. Scleroderma Therapeutics Introduction
13.10.4 Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
13.10.5 Kadmon Holdings, Inc. Recent Development
13.11 Seattle Genetics, Inc.
10.11.1 Seattle Genetics, Inc. Company Details
10.11.2 Seattle Genetics, Inc. Business Overview and Its Total Revenue
10.11.3 Seattle Genetics, Inc. Scleroderma Therapeutics Introduction
10.11.4 Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.11.5 Seattle Genetics, Inc. Recent Development
13.12 Cytori Therapeutics, Inc.
10.12.1 Cytori Therapeutics, Inc. Company Details
10.12.2 Cytori Therapeutics, Inc. Business Overview and Its Total Revenue
10.12.3 Cytori Therapeutics, Inc. Scleroderma Therapeutics Introduction
10.12.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.12.5 Cytori Therapeutics, Inc. Recent Development
13.13 Fibrocell Science, Inc.
10.13.1 Fibrocell Science, Inc. Company Details
10.13.2 Fibrocell Science, Inc. Business Overview and Its Total Revenue
10.13.3 Fibrocell Science, Inc. Scleroderma Therapeutics Introduction
10.13.4 Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.13.5 Fibrocell Science, Inc. Recent Development
13.14 Chemomab
10.14.1 Chemomab Company Details
10.14.2 Chemomab Business Overview and Its Total Revenue
10.14.3 Chemomab Scleroderma Therapeutics Introduction
10.14.4 Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020)
10.14.5 Chemomab Recent Development
13.15 Corbus Pharmaceuticals Holdings, Inc.
10.15.1 Corbus Pharmaceuticals Holdings, Inc. Company Details
10.15.2 Corbus Pharmaceuticals Holdings, Inc. Business Overview and Its Total Revenue
10.15.3 Corbus Pharmaceuticals Holdings, Inc. Scleroderma Therapeutics Introduction
10.15.4 Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020)
10.15.5 Corbus Pharmaceuticals Holdings, Inc. Recent Development
13.16 Genkyotex
10.16.1 Genkyotex Company Details
10.16.2 Genkyotex Business Overview and Its Total Revenue
10.16.3 Genkyotex Scleroderma Therapeutics Introduction
10.16.4 Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020)
10.16.5 Genkyotex Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Scleroderma Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Scleroderma Therapeutics Revenue
Table 3. Ranking of Global Top Scleroderma Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Immunosuppressors
Table 6. Key Players of Phosphodiesterase 5 Inhibitors - PHA
Table 7. Key Players of Endothelin Receptor Antagonists
Table 8. Key Players of Prostacyclin Analogues
Table 9. Key Players of Calcium Channel Blockers
Table 10. Key Players of Analgesics
Table 11. Key Players of Others
Table 12. COVID-19 Impact Global Market: (Four Scleroderma Therapeutics Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Scleroderma Therapeutics Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact
Table 17. Global Scleroderma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Scleroderma Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Scleroderma Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Scleroderma Therapeutics Market Share by Regions (2015-2020)
Table 21. Global Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Scleroderma Therapeutics Market Growth Strategy
Table 27. Main Points Interviewed from Key Scleroderma Therapeutics Players
Table 28. Global Scleroderma Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 29. Global Scleroderma Therapeutics Market Share by Players (2015-2020)
Table 30. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019)
Table 31. Global Scleroderma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Scleroderma Therapeutics Product Solution and Service
Table 34. Date of Enter into Scleroderma Therapeutics Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. Global Scleroderma Therapeutics Market Size Share by Type (2015-2020)
Table 38. Global Scleroderma Therapeutics Revenue Market Share by Type (2021-2026)
Table 39. Global Scleroderma Therapeutics Market Size Share by Application (2015-2020)
Table 40. Global Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 41. Global Scleroderma Therapeutics Market Size Share by Application (2021-2026)
Table 42. North America Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 44. North America Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 45. North America Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 46. North America Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 47. North America Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 48. Europe Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 50. Europe Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 52. Europe Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 54. China Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 55. China Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 56. China Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 57. China Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 58. China Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 59. China Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 60. Japan Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 62. Japan Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 64. Japan Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 68. Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 70. Southeast Asia Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 72. India Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 73. India Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 74. India Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 75. India Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 76. India Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 77. India Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 80. Central & South America Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 82. Central & South America Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 84. F. Hoffmann-La Roche AG Company Details
Table 85. F. Hoffmann-La Roche AG Business Overview
Table 86. F. Hoffmann-La Roche AG Product
Table 87. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 88. F. Hoffmann-La Roche AG Recent Development
Table 89. Bristol-Myers Squibb Company Company Details
Table 90. Bristol-Myers Squibb Company Business Overview
Table 91. Bristol-Myers Squibb Company Product
Table 92. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 93. Bristol-Myers Squibb Company Recent Development
Table 94. Celgene Corporation Company Details
Table 95. Celgene Corporation Business Overview
Table 96. Celgene Corporation Product
Table 97. Celgene Corporation Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 98. Celgene Corporation Recent Development
Table 99. Argentis Pharmaceuticals, LLC Company Details
Table 100. Argentis Pharmaceuticals, LLC Business Overview
Table 101. Argentis Pharmaceuticals, LLC Product
Table 102. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 103. Argentis Pharmaceuticals, LLC Recent Development
Table 104. Bayer AG Company Details
Table 105. Bayer AG Business Overview
Table 106. Bayer AG Product
Table 107. Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 108. Bayer AG Recent Development
Table 109. Boehringer Ingelheim International GmbH Company Details
Table 110. Boehringer Ingelheim International GmbH Business Overview
Table 111. Boehringer Ingelheim International GmbH Product
Table 112. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 113. Boehringer Ingelheim International GmbH Recent Development
Table 114. Akashi Therapeutics Company Details
Table 115. Akashi Therapeutics Business Overview
Table 116. Akashi Therapeutics Product
Table 117. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 118. Akashi Therapeutics Recent Development
Table 119. Prometic Life Sciences, Inc. Business Overview
Table 120. Prometic Life Sciences, Inc. Product
Table 121. Prometic Life Sciences, Inc. Company Details
Table 122. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 123. Prometic Life Sciences, Inc. Recent Development
Table 124. Emerald Health Pharmaceuticals Company Details
Table 125. Emerald Health Pharmaceuticals Business Overview
Table 126. Emerald Health Pharmaceuticals Product
Table 127. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 128. Emerald Health Pharmaceuticals Recent Development
Table 129. Kadmon Holdings, Inc. Company Details
Table 130. Kadmon Holdings, Inc. Business Overview
Table 131. Kadmon Holdings, Inc. Product
Table 132. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 133. Kadmon Holdings, Inc. Recent Development
Table 134. Seattle Genetics, Inc. Company Details
Table 135. Seattle Genetics, Inc. Business Overview
Table 136. Seattle Genetics, Inc. Product
Table 137. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 138. Seattle Genetics, Inc. Recent Development
Table 139. Cytori Therapeutics, Inc. Company Details
Table 140. Cytori Therapeutics, Inc. Business Overview
Table 141. Cytori Therapeutics, Inc. Product
Table 142. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 143. Cytori Therapeutics, Inc. Recent Development
Table 144. Fibrocell Science, Inc. Company Details
Table 145. Fibrocell Science, Inc. Business Overview
Table 146. Fibrocell Science, Inc. Product
Table 147. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 148. Fibrocell Science, Inc. Recent Development
Table 149. Chemomab Company Details
Table 150. Chemomab Business Overview
Table 151. Chemomab Product
Table 152. Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 153. Chemomab Recent Development
Table 154. Corbus Pharmaceuticals Holdings, Inc. Company Details
Table 155. Corbus Pharmaceuticals Holdings, Inc. Business Overview
Table 156. Corbus Pharmaceuticals Holdings, Inc. Product
Table 157. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 158. Corbus Pharmaceuticals Holdings, Inc. Recent Development
Table 159. Genkyotex Company Details
Table 160. Genkyotex Business Overview
Table 161. Genkyotex Product
Table 162. Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 163. Genkyotex Recent Development
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
Table 1. Scleroderma Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Scleroderma Therapeutics Revenue
Table 3. Ranking of Global Top Scleroderma Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Scleroderma Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Immunosuppressors
Table 6. Key Players of Phosphodiesterase 5 Inhibitors - PHA
Table 7. Key Players of Endothelin Receptor Antagonists
Table 8. Key Players of Prostacyclin Analogues
Table 9. Key Players of Calcium Channel Blockers
Table 10. Key Players of Analgesics
Table 11. Key Players of Others
Table 12. COVID-19 Impact Global Market: (Four Scleroderma Therapeutics Market Size Forecast Scenarios)
Table 13. Opportunities and Trends for Scleroderma Therapeutics Players in the COVID-19 Landscape
Table 14. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 15. Key Regions/Countries Measures against Covid-19 Impact
Table 16. Proposal for Scleroderma Therapeutics Players to Combat Covid-19 Impact
Table 17. Global Scleroderma Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 18. Global Scleroderma Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 19. Global Scleroderma Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 20. Global Scleroderma Therapeutics Market Share by Regions (2015-2020)
Table 21. Global Scleroderma Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 22. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)
Table 23. Market Top Trends
Table 24. Key Drivers: Impact Analysis
Table 25. Key Challenges
Table 26. Scleroderma Therapeutics Market Growth Strategy
Table 27. Main Points Interviewed from Key Scleroderma Therapeutics Players
Table 28. Global Scleroderma Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 29. Global Scleroderma Therapeutics Market Share by Players (2015-2020)
Table 30. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019)
Table 31. Global Scleroderma Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 32. Key Players Headquarters and Area Served
Table 33. Key Players Scleroderma Therapeutics Product Solution and Service
Table 34. Date of Enter into Scleroderma Therapeutics Market
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. Global Scleroderma Therapeutics Market Size Share by Type (2015-2020)
Table 38. Global Scleroderma Therapeutics Revenue Market Share by Type (2021-2026)
Table 39. Global Scleroderma Therapeutics Market Size Share by Application (2015-2020)
Table 40. Global Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 41. Global Scleroderma Therapeutics Market Size Share by Application (2021-2026)
Table 42. North America Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 43. North America Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 44. North America Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 45. North America Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 46. North America Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 47. North America Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 48. Europe Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 49. Europe Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 50. Europe Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 51. Europe Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 52. Europe Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 53. Europe Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 54. China Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 55. China Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 56. China Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 57. China Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 58. China Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 59. China Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 60. Japan Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 61. Japan Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 62. Japan Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 63. Japan Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 64. Japan Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 65. Japan Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 66. Southeast Asia Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 67. Southeast Asia Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 68. Southeast Asia Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 69. Southeast Asia Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 70. Southeast Asia Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 71. Southeast Asia Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 72. India Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 73. India Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 74. India Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 75. India Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 76. India Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 77. India Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 78. Central & South America Key Players Scleroderma Therapeutics Revenue (2019-2020) (Million US$)
Table 79. Central & South America Key Players Scleroderma Therapeutics Market Share (2019-2020)
Table 80. Central & South America Scleroderma Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 81. Central & South America Scleroderma Therapeutics Market Share by Type (2015-2020)
Table 82. Central & South America Scleroderma Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 83. Central & South America Scleroderma Therapeutics Market Share by Application (2015-2020)
Table 84. F. Hoffmann-La Roche AG Company Details
Table 85. F. Hoffmann-La Roche AG Business Overview
Table 86. F. Hoffmann-La Roche AG Product
Table 87. F. Hoffmann-La Roche AG Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 88. F. Hoffmann-La Roche AG Recent Development
Table 89. Bristol-Myers Squibb Company Company Details
Table 90. Bristol-Myers Squibb Company Business Overview
Table 91. Bristol-Myers Squibb Company Product
Table 92. Bristol-Myers Squibb Company Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 93. Bristol-Myers Squibb Company Recent Development
Table 94. Celgene Corporation Company Details
Table 95. Celgene Corporation Business Overview
Table 96. Celgene Corporation Product
Table 97. Celgene Corporation Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 98. Celgene Corporation Recent Development
Table 99. Argentis Pharmaceuticals, LLC Company Details
Table 100. Argentis Pharmaceuticals, LLC Business Overview
Table 101. Argentis Pharmaceuticals, LLC Product
Table 102. Argentis Pharmaceuticals, LLC Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 103. Argentis Pharmaceuticals, LLC Recent Development
Table 104. Bayer AG Company Details
Table 105. Bayer AG Business Overview
Table 106. Bayer AG Product
Table 107. Bayer AG Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 108. Bayer AG Recent Development
Table 109. Boehringer Ingelheim International GmbH Company Details
Table 110. Boehringer Ingelheim International GmbH Business Overview
Table 111. Boehringer Ingelheim International GmbH Product
Table 112. Boehringer Ingelheim International GmbH Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 113. Boehringer Ingelheim International GmbH Recent Development
Table 114. Akashi Therapeutics Company Details
Table 115. Akashi Therapeutics Business Overview
Table 116. Akashi Therapeutics Product
Table 117. Akashi Therapeutics Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 118. Akashi Therapeutics Recent Development
Table 119. Prometic Life Sciences, Inc. Business Overview
Table 120. Prometic Life Sciences, Inc. Product
Table 121. Prometic Life Sciences, Inc. Company Details
Table 122. Prometic Life Sciences, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 123. Prometic Life Sciences, Inc. Recent Development
Table 124. Emerald Health Pharmaceuticals Company Details
Table 125. Emerald Health Pharmaceuticals Business Overview
Table 126. Emerald Health Pharmaceuticals Product
Table 127. Emerald Health Pharmaceuticals Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 128. Emerald Health Pharmaceuticals Recent Development
Table 129. Kadmon Holdings, Inc. Company Details
Table 130. Kadmon Holdings, Inc. Business Overview
Table 131. Kadmon Holdings, Inc. Product
Table 132. Kadmon Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 133. Kadmon Holdings, Inc. Recent Development
Table 134. Seattle Genetics, Inc. Company Details
Table 135. Seattle Genetics, Inc. Business Overview
Table 136. Seattle Genetics, Inc. Product
Table 137. Seattle Genetics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 138. Seattle Genetics, Inc. Recent Development
Table 139. Cytori Therapeutics, Inc. Company Details
Table 140. Cytori Therapeutics, Inc. Business Overview
Table 141. Cytori Therapeutics, Inc. Product
Table 142. Cytori Therapeutics, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 143. Cytori Therapeutics, Inc. Recent Development
Table 144. Fibrocell Science, Inc. Company Details
Table 145. Fibrocell Science, Inc. Business Overview
Table 146. Fibrocell Science, Inc. Product
Table 147. Fibrocell Science, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 148. Fibrocell Science, Inc. Recent Development
Table 149. Chemomab Company Details
Table 150. Chemomab Business Overview
Table 151. Chemomab Product
Table 152. Chemomab Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 153. Chemomab Recent Development
Table 154. Corbus Pharmaceuticals Holdings, Inc. Company Details
Table 155. Corbus Pharmaceuticals Holdings, Inc. Business Overview
Table 156. Corbus Pharmaceuticals Holdings, Inc. Product
Table 157. Corbus Pharmaceuticals Holdings, Inc. Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 158. Corbus Pharmaceuticals Holdings, Inc. Recent Development
Table 159. Genkyotex Company Details
Table 160. Genkyotex Business Overview
Table 161. Genkyotex Product
Table 162. Genkyotex Revenue in Scleroderma Therapeutics Business (2015-2020) (Million US$)
Table 163. Genkyotex Recent Development
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Scleroderma Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Immunosuppressors Features
Figure 3. Phosphodiesterase 5 Inhibitors - PHA Features
Figure 4. Endothelin Receptor Antagonists Features
Figure 5. Prostacyclin Analogues Features
Figure 6. Calcium Channel Blockers Features
Figure 7. Analgesics Features
Figure 8. Others Features
Figure 9. Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Systemic Case Studies
Figure 11. Localized Case Studies
Figure 12. Scleroderma Therapeutics Report Years Considered
Figure 13. Global Scleroderma Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Scleroderma Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Scleroderma Therapeutics Market Share by Players in 2019
Figure 18. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2019
Figure 20. North America Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. F. Hoffmann-La Roche AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 29. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 31. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 33. Argentis Pharmaceuticals, LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 35. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 37. Boehringer Ingelheim International GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 39. Akashi Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 41. Prometic Life Sciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 43. Emerald Health Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 45. Kadmon Holdings, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 47. Seattle Genetics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 49. Cytori Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 51. Fibrocell Science, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 53. Chemomab Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 55. Corbus Pharmaceuticals Holdings, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 57. Genkyotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Figure 1. Global Scleroderma Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Immunosuppressors Features
Figure 3. Phosphodiesterase 5 Inhibitors - PHA Features
Figure 4. Endothelin Receptor Antagonists Features
Figure 5. Prostacyclin Analogues Features
Figure 6. Calcium Channel Blockers Features
Figure 7. Analgesics Features
Figure 8. Others Features
Figure 9. Global Scleroderma Therapeutics Market Share by Application: 2020 VS 2026
Figure 10. Systemic Case Studies
Figure 11. Localized Case Studies
Figure 12. Scleroderma Therapeutics Report Years Considered
Figure 13. Global Scleroderma Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Scleroderma Therapeutics Market Share by Regions: 2020 VS 2026
Figure 15. Global Scleroderma Therapeutics Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Scleroderma Therapeutics Market Share by Players in 2019
Figure 18. Global Top Scleroderma Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Scleroderma Therapeutics as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Scleroderma Therapeutics Revenue in 2019
Figure 20. North America Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Scleroderma Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. F. Hoffmann-La Roche AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. F. Hoffmann-La Roche AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 29. Bristol-Myers Squibb Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Bristol-Myers Squibb Company Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 31. Celgene Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Celgene Corporation Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 33. Argentis Pharmaceuticals, LLC Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Argentis Pharmaceuticals, LLC Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 35. Bayer AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Bayer AG Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 37. Boehringer Ingelheim International GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Boehringer Ingelheim International GmbH Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 39. Akashi Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Akashi Therapeutics Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 41. Prometic Life Sciences, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Prometic Life Sciences, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 43. Emerald Health Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Emerald Health Pharmaceuticals Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 45. Kadmon Holdings, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Kadmon Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 47. Seattle Genetics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Seattle Genetics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 49. Cytori Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Cytori Therapeutics, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 51. Fibrocell Science, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Fibrocell Science, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 53. Chemomab Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Chemomab Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 55. Corbus Pharmaceuticals Holdings, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Corbus Pharmaceuticals Holdings, Inc. Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 57. Genkyotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Genkyotex Revenue Growth Rate in Scleroderma Therapeutics Business (2015-2020)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
